KBM5 T315I Cell Line格列卫-伊马替尼耐药细胞株KBM5-T315I BioVector NTCC质粒载体菌种细胞基因保藏中心
- 价 格：¥986835
- 货 号：KBM5 T315I Cell Line格列卫-伊马替尼耐药细胞株KBM5-T315I
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
KBM5 T315I Cell Line格列卫-伊马替尼耐药细胞株KBM5-T315I BioVector NTCC质粒载体菌种细胞基因保藏中心
KBM5 T315I Cell LineCat No.: NTCC510625Disease: Chronic myelogenous leukemia, BCR-ABL1 positive Species of origin: Homo sapiensSex of cell: FemaleCategory: Cancer cell lineKBM-5 is a leukemic cell line derived from a patient in the blastic phase of chronic myelogenous leukemia. The cells exhibited multiple copies of the Philadelphia chromosome, and a high level of p210Bcr-Abl kinase activity was detected with rabbit anti-Abl and anti-Bcr (exon 3) peptide antisera. Use of specific primers and polymerase chain reaction followed by Southern blotting revealed that KBM-5 cells carried a bcr3-ABLII splice junction. While a normal BCR message was detected, no normal ABL message was found. The cells were phenotypically myeloid with monocytic differentiation. The high cloning efficiency in semisolid media was independent of the presence of exogenous colony-stimulating factors. In vitro exposure to induces of differentiation, such as retinoic acid, dimethyl sulfoxide, or hemin, failed to influence the growth rate of the cells and their level of differentiation. KBM-5 cells are highly resistant to the antiproliferative action of recombinant alpha- and gamma-interferons. Although sensitive to recombinant tumor necrosis factor alpha, they were completely resistant to natural killer cell action. KBM-5 cells constitutively expressed mRNA for tumor necrosis factor alpha but not for gamma-interferon, other interleukins, or hematopoietic growth factors. The KBM-5 cells that were transplanted into SCID mice manifested metastatic potential and tissue invasiveness similar to the way leukemic cells in humans do. This new KBM-5 cell line represents a helpful model for examining in vitro and in vivo modulation of the growth and properties of leukemic cells by using biological and chemotherapeutic agents.KBM5-T315I line was derived from KBM5 by exposing to increasing concentrations of Gleevec, leading to the selection of survival clone harboring T315I mutation. Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. KBM5-T315I cells showed decreased cell proliferation, lactate production, fatty acid synthesis, ROS production, and down regulation of mRNA expression related to ROS scavengers, such as SOD2, catalase, GCLm, and GPx1.
Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net
KBM5 T315I Cell LineCat No.: NTCC510625Disease: Chronic myelogenous leukemia, BCR-ABL1 positive Species of origin: Homo sapiensSex of cell: FemaleCategory: Cancer cell lineKBM-5 is a leukemic cell line derived from a patient in the blastic phase of chronic myelogenous leukemia. The cells exhibited multiple copies of the Philadelphia chromosome, and a high level of p210Bcr-Abl kinase activity was detected with rabbit anti-Abl and anti-Bcr (exon 3) peptide antisera. Use of specific primers and polymerase chain reaction followed by Southern blotting revealed that KBM-5 cells carried a bcr3-ABLII splice junction. While a normal BCR message was detected, no normal ABL message was found. The cells were phenotypically myeloid with monocytic differentiation. The high cloning efficiency in semisolid media was independent of the presence of exogenous colony-stimulating factors. In vitro exposure to induces of differentiation, such as retinoic acid, dimethyl sulfoxide, or hemin, failed to influence the growth rate of the cells and their level of differentiation. KBM-5 cells are highly resistant to the antiproliferative action of recombinant alpha- and gamma-interferons. Although sensitive to recombinant tumor necrosis factor alpha, they were completely resistant to natural killer cell action. KBM-5 cells constitutively expressed mRNA for tumor necrosis factor alpha but not for gamma-interferon, other interleukins, or hematopoietic growth factors. The KBM-5 cells that were transplanted into SCID mice manifested metastatic potential and tissue invasiveness similar to the way leukemic cells in humans do. This new KBM-5 cell line represents a helpful model for examining in vitro and in vivo modulation of the growth and properties of leukemic cells by using biological and chemotherapeutic agents.KBM5-T315I line was derived from KBM5 by exposing to increasing concentrations of Gleevec, leading to the selection of survival clone harboring T315I mutation. Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. KBM5-T315I cells showed decreased cell proliferation, lactate production, fatty acid synthesis, ROS production, and down regulation of mRNA expression related to ROS scavengers, such as SOD2, catalase, GCLm, and GPx1.
Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net
- 公告/新闻
免费订购电话: 400-800-2947